01/30/2026
Dry age-related macular degeneration (AMD) accounts for 90% of all AMD cases and affects millions of people in the U.S., causing progressive vision loss or even blindness.
A new, innovative treatment is now available that harnesses the power of therapeutic red light therapy—requiring no injections, surgery, or medications.
Price Vision Group, our research partner, has the specialized equipment and trained staff to offer this treatment. We are partnering to track patient outcomes, as data continues to emerge on who benefits most from this therapy.
Please share this post to your newsfeed to help us spread awareness—and hope—for those facing uncertainty about the future of their vision.